Back close

317O – Bortezomib based versus melphalan based regimen as induction chemotherapy for primary AL amyloidosis with cardiac involvement and factors predicting early mortality

Publication Type : Conference Proceedings

Publisher : Elsevier

Source : ESMO Asia Congress. Singapore 664. Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx664, https://doi.org/10.1093/annonc/mdx664

Url : https://www.sciencedirect.com/science/article/pii/S0923753419562858?via%3Dihub

Campus : Kochi

School : School of Medicine

Year : 2017

Abstract : Background: The prognosis of AL amyloidosis depends on the number and severity of organ involvement, especially cardiac. Nearly half of them die within a year of diagnosis. Chemotherapy has shown to slightly improve survival. We have compared the outcomes between the two different regimens and independent factors predicting early mortality.

Cite this Research Publication : Srinivasalu V K, Subramaniam M, Shanmugam A, Philip A, Susan A, Prabhu R, Unni M, Sidharthan N, Jose W, Smitha NV, Pavithran K (2017) Bortezomib based versus melphalan based regimen as induction chemotherapy for primary AL amyloidosis with cardiac involvement and factors predicting early mortality In: ESMO Asia Congress. Singapore 664. Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx664, https://doi.org/10.1093/annonc/mdx664

Admissions Apply Now